You are viewing a preview of...
MLL and MLL-fusion Induced Degradation by Disulfiram and Diethyldithiocarbamate as a Treatment for Leukaemia and Cancer
The inhibition promoted by disulfiram has great potential in the treatment of MLL leukaemia due to its well-characterised drug profile

Background
Mixed lineage leukaemia (MLL) is an aggressive blood cancer that occurs in paediatric and adult patients. The “mixed” and pluripotent character of MLL makes it difficult to treat and is associated with particularly poor clinical outcomes. Currently, therapies for MLL involve chemotherapy with non-selective cell-killing in the bone marrow and other organs. Therefore, targeted therapeutics against oncogenic MLL fusion proteins that reduce or mitigate side effects would be desirable.
Technology Overview
This technology relates to the treatment of mixed lineage leukaemia (MLL) through the use of disulfiram, a compound that induces the proteolysis of the oncogenic MLL fusion proteins associated with this type of leukaemia. The inhibition promoted by disulfiram has great potential in the treatment of MLL leukaemia
Log in or create a free account to continue reading